FDA Orange Book · active-ingredient family
Safflower oil; soybean oil
Safflower oil; soybean oil is approved in 2 FDA applications, with therapeutic-equivalence codes, listed patents, and marketing exclusivity from the FDA Orange Book.
Reference-listed drug:LIPOSYN II 10% · NDA 018997
2
Brand (NDA)
0
Generics (ANDA)
0
Listed patents
0
Exclusivity periods
Brand (NDA) products · injectable
| Product | Applicant | Application | TE | Approved | |
|---|---|---|---|---|---|
| LIPOSYN II 10% | HOSPIRA | NDA 018997 | — | Aug 27, 1984 | |
| LIPOSYN II 20% | HOSPIRA | NDA 018991 | — | Aug 27, 1984 |
Listed patents
No patents are listed against this product in the Orange Book. Listed patents reflect those the NDA holder submits under 21 U.S.C. 355 and are not exhaustive.
Safflower oil; soybean oil — frequently asked questions
Generics, reference-listed drug, patents, and exclusivity for this active ingredient, from the FDA Orange Book.
